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Background: Injection of adipose-derived mesenchymal stromal cells (ASCs) into
murine knee joints after induction of inflammatory collagenase-induced osteoarthritis
(CiOA) reduces development of joint pathology. This protection is only achieved when
ASCs are applied in early CiOA, which is characterized by synovitis and high S100A8/A9
and IL-1β levels, suggesting that inflammation is a prerequisite for the protective effect
of ASCs. Our objective was to gain more insight into the interplay between synovitis and
ASC-mediated amelioration of CiOA pathology.
Methods: CiOA was induced by intra-articular collagenase injection. Knee joint sections
were stained with hematoxylin/eosin and immunolocalization of polymorphonuclear
cells (PMNs) and ASCs was performed using antibodies for NIMP-R14 and CD271,
respectively. Chemokine expression induced by IL-1β or S100A8/A9 was assessed with
qPCR and Luminex. ASC-PMN co-cultures were analyzed microscopically and with
Luminex for inflammatory mediators. Migration of PMNs through transwell membranes
toward conditioned medium of non-stimulated ASCs (ASCNS-CM) or IL-1β-stimulated
ASCs (ASCIL-1β-CM) was examined using flow cytometry. Phagocytic capacity of PMNs
was measured with labeled zymosan particles.
Results: Intra-articular saline injection on day 7 of CiOA increased synovitis
after 6 h, characterized by PMNs scattered throughout the joint cavity and
the synovium. ASC injection resulted in comparable numbers of PMNs
which clustered around ASCs in close interaction with the synovial lining.
IL-1β-stimulation of ASCs in vitro strongly increased expression of PMN-attracting
chemokines CXCL5, CXCL7, and KC, whereas S100A8/A9-stimulation did not. In
agreement, the number of clustered PMNs per ASC was significantly increased
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after 6 h of co-culturing with IL-1β-stimulated ASCs. Also migration of PMNs toward
ASCIL-1β-CM was significantly enhanced (287%) when compared to ASCNS-CM.
Interestingly, association of PMNs with ASCs significantly diminished KC protein release
by ASCs (69% lower after 24 h), accompanied by reduced release of S100A8/A9 protein
by the PMNs. Moreover, phagocytic capacity of PMNs was strongly enhanced after
priming with ASCIL-1β-CM.
Conclusions: Local application of ASCs in inflamedCiOA knee joints results in clustering
of attracted PMNs with ASCs in the synovium, which is likely mediated by IL-1β-induced
up-regulation of chemokine release by ASCs. This results in enhanced phagocytic
capacity of PMNs, enabling the clearance of debris to attenuate synovitis.
Keywords: CiOA, synovitis, adipose-derived mesenchymal stromal cells, interleukin-1β, chemokines,
PMNs, phagocytosis
BACKGROUND
Osteoarthritis (OA) affects various tissues within the joint
and is characterized by destruction of cartilage, formation of
osteophytes and eventually disability. Additionally, in joints of
many OA patients synovial inflammation is evident (1, 2), which
could be ignited by several factors including damage-associated
molecular patterns (DAMPs) (3), crystals (4), or cartilage
components (5). Synovitis is likely important for removal of this
tissue debris, thereby promoting repair processes (6), but on
the other hand, synovial inflammation may also aggravate joint
destruction via prolonged release of pro-inflammatory factors
and cartilage-degrading enzymes (7).
Bone marrow (BM)-derived mesenchymal stromal cells
(MSCs) exhibit immunosuppressive effects, and are therefore
seen as a potential therapeutic tool for various inflammatory
diseases (8, 9). Because adipose-derived mesenchymal stromal
cells (ASCs) share multiple properties with BM-derived MSCs,
are more abundant (5% of nucleated cells in adipose tissue vs.
0.0001–0.001% in BM), and can more easily be obtained, adipose
tissue is an attractive alternative source ofmultipotentMSCs (10).
Over the recent years, several clinical trials have been
conducted to treat OA patients with ASCs (11). In multiple
proof-of-concept trials, including several dose-escalation
studies, no severe adverse events or complications were
found (12–15). The first phase I dose-escalating clinical
Abbreviations: ANOVA, one-way analysis of variance; ASC, adipose-derived
mesenchymal stromal cell; BM, bone marrow; BSA, bovine serum albumin;
CD, cluster of differentiation; cDNA, complementary DNA; CiOA, collagenase-
induced OA; CM, conditioned medium; Ct, cycle threshold; CXCL, C-X-C
motif chemokine ligand; DAMP, damage-associated molecular pattern; DMM,
destabilization of the medial meniscus; ELISA, enzyme-linked immunosorbent
assay; FI, fluorescence intensity; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; HE, hematoxylin/eosin; ICAM-1, intercellular adhesion
molecule-1; IL, interleukin; JNK, c-Jun N-terminal kinase; KC, keratinocyte
chemoattractant; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein
1; MGG, May-Grünwald Giemsa; mRNA, messenger RNA; MSC, mesenchymal
stromal cell; NF-κB, nuclear factor κB; ND, not detectable; NS, no stimulation;
OA, osteoarthritis; PBS, phosphate-buffered saline; PMN, polymorphonuclear
cell; qRT-PCR, quantitative real-time polymerase chain reaction; SD, standard
deviation; TLR, Toll-like receptor; U, unit.
trial, ADIPOA, showed that ASC injection is safe and
well-tolerated in patients with knee osteoarthritis, and
provided encouraging preliminary evidence of efficacy (16).
The mechanism by which ASCs reduce joint pathology
remains largely unknown. Recently we described that
local application of ASCs in murine knee joints with early
collagenase-induced OA (CiOA) ameliorated end stage joint
destruction (17). Moreover, ASCs rapidly suppressed synovial
thickening in early CiOA, and already 6 h after intra-articular
injection, synovial release of key pro-inflammatory factors
S100A8/A9 and interleukin (IL-)1β had significantly diminished.
Cytokine levels remained low throughout the course of the
disease measured up to day 42 after induction of the CiOA
model (18).
This suppressive effect was only found when ASCs were
applied early after induction of CiOA when synovitis was
substantial, but not when administered at a later phase
when synovitis was much lower (17). Cartilage protection
after early ASC injection was confirmed in the mild medial
meniscal destabilization model of OA in rabbits (19).
Correspondingly with these studies, intra-articular application
of ASCs early after induction of the destabilization of the
medial meniscus (DMM) model, a surgical model of OA
in which synovial inflammation is scant, had no effect
on development of joint destruction (18). These findings
indicate that the protective effect of ASCs is promoted
by synovitis.
Many studies have suggested that ASCs directly suppress
inflammation and tissue pathology solely by producing anti-
inflammatory factors (20). However, previous results from our
lab suggest that other mechanisms may also be relevant. We
found that ASCs associate with the inflamed synovium within
24 h after intra-articular injection, but no more ASCs were
detected 5 days after injection (17). Furthermore, a recent
phase I clinical trial reported that a low dose of intra-
articularly injected ASCs reduced pain levels and improved joint
function (16). Based on these findings we hypothesized that
early application of ASCs in inflammatory OA joints results
in a rapid, potent protection, which remains effective up till
later stages.
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The aim of the present study was to investigate the underlying
mechanism of ASC-mediated amelioration of joint destruction
during CiOA. We started off with a histological analysis of CiOA
joints shortly after intra-articular injection of ASCs. These in vivo
observations provided the basis for further examination in vitro.
We analyzed the result of ASC stimulation with inflammatory
factors which are present in early CiOA on their chemokine
production, as well as their physical interactions with immune
cells. Additionally, to identify a possible mechanism by which
ASCs may interrupt the vicious cycle of inflammation and joint
destruction in CiOA, the immunomodulatory effects of ASCs on
the attracted immune cells were determined.
METHODS
Animals
Female C57BL/6NRj mice were obtained from Janvier. Mice
were used at the age of 12 weeks old and were housed in
filter-top cages with corncob bedding under standard conditions.
A standard diet and tap water was available ad libitum.
Group sizes were based on expected variation and a power
of 80%. All animal studies were according to the Dutch
law and were approved by the local Animal Experimentation
Committee (RU-DEC 2013-215).
Induction of CiOA
CiOA was induced by two unilateral, intra-articular injections of
1U collagenase type VII from Clostridium histolyticum (Sigma-
Aldrich) into knee joints of 16 C57BL/6NRj mice on days 0 and
2, causing damage to collateral and cruciate ligaments leading
to local instability of the knee joint. This resulted in an OA-
like phenotype with chronic synovial activation and cartilage
destruction as was presented before in the article that initially
described this OA-model (21). Day 42 was taken to model end
point of the disease. Contralateral saline-injected knee joints were
used as controls.
ASC Isolation and Culture
Murine ASCs were isolated from the heterogeneous crude
stromal fraction of adipose tissue surrounding the inguinal
lymph nodes of C57BL/6NRj donor mice, by digestion of the
fat tissue with Collagenase A (Roche) and selection by adhesion
onto plastic overnight. ASCs were cultured according to standard
procedures in DMEM/F12 (Gibco) supplemented with 10%
newborn calf serum (Sigma-Aldrich), 1% penicillin/streptomycin
(Invitrogen), 0.5% amphotericin B (Invitrogen), 16µM biotin
(Sigma-Aldrich), 18µM pantothenic acid (Sigma-Aldrich), and
100µM ascorbic acid (Sigma-Aldrich). Purity of the population
was checked by flow cytometry analysis of presence (>80%) of
cell markers Sca-1, CD44, CD105, and absence (<5%) of CD11b,
c-Kit, and CD34, as described earlier (17).
Human ASCs were isolated from the stromal vascular fraction
from liposuctions as previously described (16). Briefly, after
collagenase digestion of the fat tissue (NB6, Coger), the stromal
vascular fraction was seeded and selected by adhesion onto plastic
overnight. Cells were cultured according to standard procedures
in MEM (MacoPharma, Tourcoing) supplemented with human
platelet growth factor-enriched plasma, 10µg/mL ciprofloxacin,
and 1 U/mL heparin. Purity of the population was checked
by flow cytometry analysis for presence of cell markers CD73
(>90%), CD90 (>90%), and CD105 (>80%) and absence of cell
markers CD14 (<2%), CD34 (<10%), and CD45 (<2%). All cells
used in experiments were<passage 3.
Intra-articular ASC Injection
On day 7 after induction of CiOA, 20,000 ASCs in 6 µL saline
supplemented with 1% bovine serum albumin (BSA) fraction
V (Sigma-Aldrich), were injected intra-articularly in both knees
of 8 mice. Eight mice with CiOA were injected bilaterally with
only saline supplemented with 1% BSA as control. In a separate
experiment, three groups of 22 mice with CiOA were injected
intra-articularly with either 20,000 ASCs or 100,000 ASCs in 6
µL saline supplemented with 1% BSA fraction V, or only saline
supplemented with 1% BSA as control, on day 7 after induction
of the model. Before injection, the viability of the ASCs was
determined using trypan blue (Sigma-Aldrich) uptake and no cell
death was observed.
Immunohistochemistry
Both left and right total knee joints of 16 mice were collected
6 h after ASC injection, as well as the right joints with CiOA of
33 mice on days 14 and 42 after induction of the model. Joints
were fixed in 4% formalin, decalcified in 4% formic acid buffered
in phosphate-buffered saline (PBS) and embedded in paraffin.
Coronal sections (7µm) were stained with hematoxylin/eosin
(HE). Immunostaining of total knee joints was performed to
visualize the presence of polymorphonuclear cells (PMNs) with
the specific antibody NIMP-R14 (kind gift from M. Strath,
National Institute for Medical Research, London, UK). Briefly,
after deparaffinization and antigen retrieval with trypsin for
5min, sections were stained for 1 h with NIMP-R14 antibody,
followed by horseradish peroxidase-conjugated rabbit anti-rat
antibody for 1 h. PMN influx was quantified separately as
infiltrate in the synovium and exudate in the joint cavity, which
was then combined to an average total PMN influx (arbitrary
score, 0–3). The localization of ASCs was visualized with
antibodies against CD271 (AP07713PU-N, OriGene). Briefly,
after deparaffinization and antigen retrieval in citrate buffer,
sections were stained for 1 h with CD271 antibody, followed
by biotinylated anti-rabbit antibody for 30min and horseradish
peroxidase-conjugated avidin–biotin complexes for 30min. All
sections were developed with diaminobenzidine (Sigma-Aldrich)
and counterstained with hematoxylin.
In vitro ASC Stimulation
Murine and human ASCs were plated in a 24 wells plate (80%
confluency) and after adhesion overnight, cells were stimulated
for 24 h with 1µg/ml S100A8 or S100A9 [produced in our
facilities (22)], various concentrations of IL-1β (0.1, 1, and
10 ng/ml) [murine: kind gift from I. G. Otterness (Pfizer Central
Research, Groton, CT); human: R&D Systems], or a combination.
100 ng/ml LPS was used as a control for the presence of Toll-like
receptor (TLR)4 on the cell membrane of ASCs.
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Preparation of RNA and Quantitative
Real-Time Polymerase Chain Reaction
(qRT-PCR)
Stimulated cells were lysed in TRI-reagent (Sigma-Aldrich)
followed by RNA isolation according to the manufacturer’s
protocol. The RNA was reverse transcribed into cDNA as
previously described (23). mRNA levels of chemokines were
detected using a StepOnePlus qRT-PCR system (Applied
Biosystems) using SYBRgreen master mix (Applied Biosystems)
and specific primers (Biolegio; Table 1). Relative quantification
of the qRT-PCR signals was performed by correcting the Ct
value of the gene of interest for glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) expression (–1Ct).
Measurement of Protein Levels in Culture
Supernatants
Culture supernatants were collected to analyze protein levels.
The release of keratinocyte chemoattractant (KC) and IL-8 were
measured using Luminex multianalyte technology, using the Bio-
Rad Bio-PlexTM 200 System with specific magnetic beads. Protein
levels of S100A8/A9 in these supernatants was quantified by a
sandwich enzyme-linked immunosorbent assay (ELISA) specific
for murine S100A8/A9 as described previously (24).
Clustering Assay
Murine primary bone marrow (BM)-PMNs were freshly
isolated from femurs of C57BL/6NRj mice with MACS
microbeads specific for Ly6B.2 (Miltenyi Biotec) according to
the manufacturer’s protocol. Murine ASCs were plated in a
24 wells plate (50% confluency), and after adhesion overnight,
freshly isolated BM-PMNs were added in a 1:10 ratio and
cultured with or without 1 ng/ml IL-1β in 50% ASC medium
and 50% PMN medium [RPMI (Gibco) supplemented with 10%
fetal calf serum (Sigma-Aldrich) and 1% penicillin/streptomycin
(Invitrogen)]. After 3, 6, 24, and 48 h supernatants were collected
for measurement of protein release upon clustering. Moreover,
after 6 h, the culture medium was removed and non-adherent
cells were vigorously washed away during the several steps of
fixing and staining the attached cells in the plate with May-
Grünwald Giemsa (MGG). The number of clustering cells was
quantified in pictures taken at five separate areas in the well using
ImageJ 1.46r software. A cluster was defined as an adherent ASC
with at least one PMN attached on its surface.
Preparation of Conditioned Medium
Conditioned medium (CM) from ASCs was collected after
24 h culture without stimulation (ASCNS-CM), or after IL-
1β stimulation (ASCIL-1β-CM). In the latter case ASCs were
stimulated for 24 h with 1 ng/ml IL-1β, washed twice with saline
to remove all exogenous IL-1β, and cultured for another 24 h with
fresh ASC culture medium before collection. CM was filtered
before use in the migration and phagocytosis assays described
below and stored at−20◦C when not used immediately.
Migration Assay
ASCNS-CM was supplemented with 100 ng/ml KC (R&D
Systems) as positive control, and with 25 ng/ml monocyte
chemotactic protein 1 (MCP-1) or 1 ng/ml IL-1β as negative
controls. CMs were added to the lower compartment of 3µm
transwell inserts (Costar). 500,000 freshly isolated primary BM-
PMNs in ASCNS-CM were placed in the top compartment of the
transwell inserts and incubated for 2 h.Migrated cells in the lower
compartment were collected and quantified with flow cytometry
after addition of 123count eBeads
TM
Counting Beads (Thermo
Fisher Scientific).
Phagocytosis Assay
Freshly MACS-isolated primary murine BM-PMNs and human
blood PMNs (MACSxpress R© Whole Blood Neutrophil Isolation
Kit, Miltenyi Biotec) were incubated at 37◦C for 1 h with ASCNS-
CM, ASCIL-1β-CM (without exogenous IL-1β), or fresh ASC
culture medium as negative control. After washing with PBS,
cells were incubated with pHrodoTM Red Zymosan BioParticles R©
(Life Technologies) at 37◦C for 1 h. Next, the phagocytic
capacity was assessed by measuring fluorescence intensity (FI)
using a Clariostar Monochromator Microplate Reader (BMG
LABTECH). The FI was corrected for the average background
fluorescence measured in triplicate in samples containing
no cells.
Statistical Analysis
Statistical analyses were performed using Graphpad Prism
version 5.03. Differences between groups were tested using a
Student’s t-test or a one-way analysis of variance (ANOVA),
followed by a Dunnett’s posttest or a Bonferroni Multiple
Comparison posttest. P-values lower than 0.05 were considered
significant. Results are expressed as mean values ± standard
deviation (SD).
TABLE 1 | Primers used for qRT-PCR.
Gene Forward primer Reverse primer
mGAPDH 5′-GGCAAATTCAACGGCACA-3′ 5′-GTTAGTGGGGTCTCGCTCCTG-3′
mCXCL5 5′-GCTCCTGTGATAAAGAAAATCATTCA-3′ 5′-CGAGTGCATTCCGCTTAGCT-3′
mCXCL7 5′-CACTGTGCTGATGTGGAAGTGATAG-3′ 5′-TTTGGGTCCAGGCACGTTT-3′
mKC 5′-TGGCTGGGATTCACCTCAA-3′ 5′-GAGTGTGGCTATGACTTCGGTTT-3′
hGAPDH 5′-ATCTTCTTTTGCGTCGCCAG-3′ 5′-TTCCCCATGGTGTCTGAGC-3′
hIL-8 5′-AGAAGTTTTTGAAGAGGGCTGAGA-3′ 5′-CAGACCCACACAATACATGAAGTG-3′
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RESULTS
PMNs Reallocate and Cluster With ASCs in
Knee Joints With Early CiOA After
Intra-articular ASC Injection
To investigate the acute ameliorating effects of ASCs, we
injected 20,000 ASCs in murine knee joints on day 7 after
induction of CiOA, when synovitis is high. An increased number
of immune cells was observed within the joint cavity 6 h
after intra-articular ASC injection (Figure 1B). Interestingly,
this cell influx was also found in the saline-injected control
CiOA knee joints (Figure 1A). Morphological screening of HE-
stained sections showed that the majority of the attracted
cells in both saline- and ASC-injected CiOA knee joints had
a PMN phenotype (Figures 1C,D) which was confirmed by
immune staining using the PMN-specific antibody NIMP-R14.
We observed that injection of saline caused an influx of
PMNs scattered throughout the joint (Figure 1E). Interestingly,
after injection of ASCs the attracted PMNs were found in
aggregates along the synovial lining layer (Figure 1F). Twenty
four hours after ASC injection, the number of PMNs was
greatly reduced in both the saline- and ASC-injected CiOA
joints, suggesting that the reallocation of PMNs is short-
lasting (Figure 1G). ASC injection in naïve joints resulted
in less PMN influx and no accumulation of cells nearby
the synovium (Figure 1H). Quantification of the attraction of
PMNs showed that both ASC and control injections result
in a significantly elevated influx of PMNs in CiOA knees
compared to naïve joints (Figure 1I). This indicates that an
injection in an already inflamed OA knee joint in itself causes
a rapid flare leading to a transient attraction of immune cells.
Interestingly, at higher magnification we observed a clustering
of PMNs around cells we supposed to be ASCs based on
their size (arrow in Figure 1J), which was confirmed with
immunolocalization of ASCs using an antibody against the
specificmarker CD271 (Figure 1K). These in vivo results possibly
designate an underlying mechanism for ASC-mediated joint
protection. Therefore they were a prelude for the following
in vitro studies in which we investigated the clustering of
PMNs with ASCs in more detail to gain insight into this
possible mechanism.
Expression of PMN-Attracting Chemokines
by ASCs Is Elevated by IL-1β in vitro
First, we investigated whether the apparent preference of PMNs
to co-localize with the ASCs is induced by inflammatory
mediators that are present during inflammatory OA. Therefore,
we determined if S100A8 and IL-1β, which are predominantly
elevated during the early stage of CiOA, enhanced the production
of the PMN-attracting chemokines C-X-C motif chemokine
ligand 5 (CXCL5), CXCL7, and KC by murine ASCs. A
significant elevation in gene expression of these chemokines
was found after 24 h stimulation with IL-1β (Figure 2A), with
a maximal increase after stimulation with only 1 ng/ml IL-1β
(70, 38, and 107, fold increase for CXCL5, CXCL7, and KC,
respectively, P < 0.001). KC showed the strongest up-regulation
of gene expression and is generally accepted as the main PMN-
attracting chemokine, which typically shows a very specific and
potent attraction of PMNs. Therefore, we determined protein
levels of KC as a representative PMN-attracting chemokine
in culture supernatants and found a 22-fold increase after
stimulation with only 1 ng/ml IL-1β (Figure 2B). Unexpectedly,
stimulation with high levels of S100A8 (1µg/ml) did not
enhance chemokine gene expression or protein levels. Moreover,
a combination of S100A8 and IL-1β did not alter the effect
of IL-1β.
To extrapolate our findings in murine ASCs to the human
situation, we next stimulated ASCs obtained from human adipose
tissue for 24 h with S100A8, S100A9, IL-1β, or a combination
of S100A9 and IL-1β, to confirm that ASC-mediated attraction
of PMNs is also plausible to be present in ASC-injected OA
patients. Like in murine ASCs, low levels of IL-1β (0.1 ng/ml)
already gave a significant 355-fold increase in gene expression
(Figure 2C) and a 26-fold increase in protein levels (Figure 2D)
of IL-8, the human functional homolog of KC (P < 0.001). In
contrast, high levels of S100A8 and S100A9 (1µg/ml) did not
elevate IL-8 levels.
Clustering of PMNs With ASCs Is
Enhanced by IL-1β in vitro
To further study the tendency of the attracted PMNs to cluster
with ASCs, murine primary PMNs and adherent murine ASCs
were co-cultured without stimulation (NS) or with 1 ng/ml IL-1β.
After 6 h, PMNs (small cells in Figure 3A) were clearly clustered
with ASCs (large cells in Figure 3A). Analysis of the number
of ASCs with clustered PMNs showed a significant increase
of 99% after co-culture in the presence of IL-1β (P < 0.01)
(Figure 3B). Moreover, the average number of PMNs clustering
per individual ASC was significantly increased with 45% after
6 h of co-culture with IL-1β (P < 0.05). These data demonstrate
that IL-1β promotes an interaction between ASCs and
PMNs (Figure 3C).
PMN Attraction by ASCs Is Increased by
IL-1β in vitro
In vivo the PMNs need to be actively attracted to the ASCs,
before they are able to cluster. Because IL-1β strongly
enhanced KC expression by ASCs, we investigated the
attraction of PMNs in vitro with conditioned medium of
non-stimulated ASCs (ASCNS-CM) and ASCs that were
stimulated with IL-1β for 24 h (ASCIL-1β-CM). Luminex
measurements confirmed that protein levels of KC in
ASCIL-1β-CM were strongly increased when compared
to ASCNS-CM (5,576 vs. 5.33 pg/ml) (Figure 4A). Using
transwell inserts we found that CM of IL-1β-stimulated
ASCs significantly increased the migration of PMNs by
287% (from 3.7 to 10.6%), confirming that ASCs attract
PMNs upon IL-1β-stimulation (Figure 4B). Likewise, ASCNS-
CM supplemented with KC as positive control showed an
increase of PMN migration by 268% (from 3.7 to 9.9%). In
contrast, the migration of PMNs toward ASCNS-CM was
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FIGURE 1 | PMNs reallocate and cluster with ASCs in knees with early CiOA after intra-articular ASC injection. (A,B) Intra-articular injection on day 7 of CiOA resulted
in attraction of immune cells within 6 h, both in the control (A) and ASC-injected (B) joints, as was shown in HE-stained total knee joint sections. (C,D) Higher
magnifications showed that the immune cells in both saline- (C) and ASC-injected (D) CiOA knee joints had a polymorphonuclear (PMN) phenotype.
(E,F) Immunohistochemistry with the specific antibody NIMP-R14 confirmed that a large number of PMNs is attracted to the joints. They were equally spread
throughout the synovium and the joint cavity in the control-injected joints (E), but in the ASC-injected joints a remarkable accumulation of PMNs along the lining was
found (F) as indicated by arrows. (G) NIMP-R14 staining showed that 24 h after ASC injection the PMN influx had largely disappeared. (H) ASC injection in naïve joints
resulted in NIMP-R14 positive cell influx, albeit lower than in CiOA joints. (I) Quantification of attracted PMNs after intra-articular injection confirmed a significantly
increased number of PMNs in CiOA joints compared to naïve joints. (J) At higher magnification we observed a clustering of PMNs around cells we supposed to be
ASCs (arrow), which was confirmed with a CD271 antibody (K) which specifically stains ASCs (arrows). Control joints were CiOA knees injected with saline
supplemented with 1% BSA. Images shown are representative for the treatment groups (n = 8 per group). Original magnification × 200 (A,B,E,F,G,H) or × 1,000
(C,D,J,K). Differences between groups were tested using a one-way ANOVA followed by a Bonferroni Multiple Comparison posttest. F, femur; S, synovium. Bars
show mean values ± SD. *P < 0.05.
low (<5%), comparable to the negative controls MCP-1 and
IL-1β alone.
IL-1β-Mediated Release of Inflammatory
Factors Is Significantly Lowered After
Clustering of PMNs With ASCs
As attraction of PMNs and clustering with ASCs in presence
of IL-1β was evident, we next determined the effect on the
inflammatory activity of these cells by analyzing the release
of KC protein after co-culture. Only minimal amounts of
KC were released by PMNs cultured alone in the presence
of IL-1β, indicating that ASCs are the main source of KC
production. When no IL-1β was added, no KC was released in
all co-cultures (Figure 5A), underlining that IL-1β is a potent
inducer of PMN-attracting chemokine release by ASCs. In
the presence of IL-1β, protein levels of KC in the supernatant
of ASCs were already significantly elevated after 3 h (P <
0.001). KC levels strongly increased to maximal elevation
(up to 65 ng/ml) after 24 h of stimulation with IL-1β which
remained at the same level after 48 h. Interestingly, 24 h of
co-culturing PMNs with ASCs in presence of IL-1β resulted in
significantly lower KC release by ASCs (69 and 76% lower after
24 and 48 h incubation, respectively) (Figure 5A), suggesting
that IL-1β-driven chemokine production by ASC is rapidly
inhibited after clustering of PMNs. Furthermore, S100A8/A9
release by PMNs was not altered in the presence of IL-1β
or in co-culture with ASCs after 3 and 6 h (Figure 5B).
However, after 24 and 48 h we found strongly elevated
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FIGURE 2 | Expression of PMN-attracting chemokines by ASCs is elevated by IL-1β in vitro. The effect of an inflammatory milieu on gene expression in ASCs was
assessed by 24 h stimulation with different pro-inflammatory mediators. (A) Murine ASCs showed a significantly increased gene expression of PMN-attracting
chemokines CXCL5, CXCL7, and KC after stimulation with IL-1β. (B) Also on protein level in the supernatant, KC was significantly up-regulated after IL-1β stimulation.
Human ASCs show a comparable elevated level of the functional KC-homolog IL-8 after IL-1β stimulation on both gene expression (C) and protein level (D). Gene
expression levels are presented as –1Ct compared to GAPDH. Closed circles represent murine samples, open triangles represent human samples [n = 4 (A,B) or 3
(C,D) per group]. Differences between non-stimulated (NS) ASCs and the several stimulations were tested using a one-way ANOVA followed by a Dunnett’s posttest.
Bars show mean values ± SD. ***P < 0.001 vs. NS ASCs.
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FIGURE 3 | Clustering of murine PMNs with ASCs is enhanced by IL-1β in vitro. The association of freshly isolated murine PMNs with adherent ASCs driven by IL-1β
was assessed in a co-culture experiment. (A) After 6 h, clustering cells were stained with May-Grünwald Giemsa and quantified. Large cells are ASCs, small cells are
PMNs. Both the number of ASCs that formed clusters with PMNs (B) and the average number of PMNs clustered per ASC (C) were significantly increased in
presence of IL-1β when compared to the non-stimulated co-cultures (NS). N = 3 per group, quantified at five separate areas per sample. Differences between the
groups were tested using a Student’s t-test. Bars show mean values ± SD. *P < 0.05, **P < 0.01.
FIGURE 4 | PMN attraction by ASCs is increased by IL-1β in vitro. The potential of IL-1β-stimulated ASCs to attract PMNs was investigated using transwell inserts.
(A) KC levels in conditioned medium (CM) of IL-1β-stimulated ASCs (ASCIL-1β-CM, no exogenous IL-1β present) were significantly elevated compared to CM of
non-stimulated ASCs (ASCNS-CM). (B) Migration of freshly isolated PMNs toward ASCIL-1β-CM as well as toward the positive control KC was significantly increased
compared to ASCNS-CM. No enhanced migration of PMNs was found in the negative controls containing MCP-1 or IL-1β. The number of migrated PMNs was
expressed as percentage of total cells added to the top compartment [n = 3 (A) or 6 (B) per group]. Differences between groups were tested using a Student’s t-test
(A) or a one-way ANOVA followed by a Dunnett’s posttest (B). Bars show mean values ± SD. ***P < 0.001 vs. ASCNS-CM.
S100A8/A9 release. S100A8/A9 release by a monoculture of
ASCs with or without IL-1β stimulation was undetectable.
Interestingly, in the presence of IL-1β-stimulated ASCs
PMNs released lower levels of S100A8/A9 when compared to
non-stimulated ASCs.
Phagocytosis by PMNs Is Enhanced After
Priming With Conditioned Medium of
IL-1β-Stimulated ASCs
To gain insight in the possible way in which the attraction
and clustering of PMNs contributes to the amelioration of OA
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FIGURE 5 | IL-1β-mediated release of inflammatory factors is significantly lowered after clustering of PMNs with ASCs. The effect of clustering of PMNs with ASCs on
protein release was determined. (A) KC release by ASCs was already significantly increased after 3 and 6 h of co-culture with PMNs in presence of IL-1β. After 24 and
48 h of co-culture with IL-1β, clustering of PMNs with ASCs resulted in a significantly lowered KC release when compared to ASCs cultured alone. (B) S100A8/A9
release was not detectable in a monoculture of ASCs, but PMNs released basal levels of S100A8/A9. These levels increased over time, but remained lower in
co-cultures of PMNs with ASCs in presence of IL-1β. N = 3 per group. Differences between groups were tested using a one-way ANOVA followed by a Bonferroni
Multiple Comparison posttest for each time point separately. Bars show mean values ± SD. ***P < 0.001. ND, not detectable.
pathology, we finally investigated whether IL-1β-activated ASCs
could enhance removal of tissue debris by inducing phagocytosis.
Already after 1 h of priming murine PMNs with ASCNS-CM,
ingestion of fluorescent zymosan particles was significantly
increased to 198% (P < 0.001) when compared to the negative
control containing only culture medium. Interestingly, priming
PMNs with ASCIL-1β-CM resulted in an even further enhanced
phagocytic capacity of 34% (P < 0.05) compared to ASCNS-CM
(Figure 6A). We next set out to demonstrate that these results
can be translated from the murine to the human situation by
using human PMNs which were primed with CM of human
ASCs. Again, we found a significant up-regulation of 84% (P <
0.01) in the phagocytic capacity of PMNs primed with ASCNS-
CM, which was further increased with an additional 42% (P <
0.01) after priming with ASCIL-1β-CM (Figure 6B). Our findings
show that IL-1β-stimulated ASCs not only attract PMNs, but
also increase their phagocytic activity thereby possibly promoting
tissue repair.
DISCUSSION
In the present study we find that local application of ASCs in
inflamed CiOA knee joints leads to rapid clustering of PMNs
around ASCs, which may designate a mechanism by which ASCs
reduce OA pathology. In vitro we uncover that IL-1β stimulates
this clustering which reduces the pro-inflammatory activity of
the PMNs. At the same time the phagocytic capacity of PMNs
is enhanced, which may substantially resolve inflammation and
potentially accelerates joint repair processes.
ASCs are known for their regenerative capacities that
enable the repair of damaged tissues such as cartilage (25),
but they also possess immunosuppressive characteristics (20,
26–28). Previously, we found that ASCs rapidly suppressed
synovitis and development of joint destruction when locally
administered to inflamed OA joints (17, 18). However, the
exact working mechanism of ASCs remained unknown, albeit
several noteworthy observations have been published. Firstly,
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FIGURE 6 | Phagocytosis by PMNs is enhanced after priming with conditioned medium of IL-1β-stimulated ASCs. The immunomodulatory effect of ASCs on PMNs
was investigated by assessment of the phagocytic capacity after priming with ASC-conditioned medium. (A) The uptake of labeled zymosan particles by murine
PMNs primed with conditioned medium (CM) of non-stimulated ASCs (ASCNS-CM) was significantly enhanced when compared to the negative control containing
fresh culture medium. Incubation of PMNs with CM of ASCs which were stimulated with IL-1β (ASCIL-1β-CM, no exogenous IL-1β is present) further enhanced
phagocytosis when compared to ASCNS-CM. (B) Human PMNs primed with ASCNS-CM showed a similar increase in phagocytic capacity when compared to culture
medium, which was even further enhanced after priming with ASCIL-1β-CM. Closed circles represent murine samples, open triangles represent human samples (n = 3
per group). Differences between groups were tested using a one-way ANOVA followed by a Bonferroni Multiple Comparison posttest. Bars show mean values ± SD.
*P < 0.05, **P < 0.01, ***P < 0.001.
a previous study demonstrated that human ASCs applied in
knee joints of normal SCID mice may reside at the site of
injection up to 6 months (29). Contrarily, we showed that
murine ASCs injected into an inflamed CiOA joint first home
to the synovium within 24 h but disappear quickly thereafter
(17). The presence of inflammation may explain the enhanced
ASC clearance in CiOA knee joints. Pro-inflammatory mediators
like IL-1β promote the migratory behavior of ASCs by elevating
chemokine release and expression of adhesion molecules such as
CD49d (integrin α4), and CD54 (ICAM-1) (30–32). Secondly,
injection of numbers as low as only 20,000 ASCs more effectively
protected against synovial inflammation in CiOA joints than a
5 times higher dose as shown in Supplementary Figure 1. This
finding was confirmed in a recent phase I clinical trial that
reported reduced pain levels and improved joint function after an
intra-articular injection of a low dose of ASCs (16). Finally, ASCs
only suppressed joint damage when applied in an inflammatory
environment (17, 18). These three crucial observations make
it unlikely that ASCs exclusively protect directly against joint
damage in our murine OA model via production of anti-
inflammatory mediators. This led to our hypothesis that early
application of ASCs in inflammatory OA joints results in a
rapid, potent protection, which remains effective up till later
stages. This protection can be achieved by interactions of ASCs
with the immune system, causing a powerful and long-lasting
amplification of their immunosuppressive capacity.
Our hypothesis is supported by the strikingly different
localization of PMNs 6 h after intra-articular injection. The saline
injection flared the smoldering synovial inflammation, resulting
in recruitment of PMNs that scattered throughout the joint,
whereas application of ASCs induced association of PMNs with
ASCs into aggregates that resided particularly on top of the
inflamed synovial lining layer. That this interaction indeed has
the potency to shift the inflammatory activity of ASCs and
PMNs was reflected by the reduced KC and S100A8/A9 release,
respectively, in our in vitro co-culture experiments. Previous
studies showed that synovial lining macrophages are crucial
in mediating S100A8/A9-driven synovitis during experimental
OA (33, 34). The physical interaction of immunomodulatory
ASC-PMN aggregates with the synovial lining may explain why
synovial S100A8/A9 protein levels were already significantly
reduced between 6 and 48 h after intra-articular ASC injection
on day 7 of CiOA (18).
Next to the altered release of inflammatory mediators,
ASCs can simultaneously direct PMNs to effectively ameliorate
ongoing inflammation in OA joints via enhanced phagocytic
activity. Apart from the clearance of debris, phagocytosis also
causes PMNs to become apoptotic. This leads to ingestion by
macrophages, which in turn start to release anti-inflammatory
and reparative cytokines thereby inducing tissue repair
(35). CM from non-stimulated ASCs already augmented
phagocytosis by PMNs, which was further increased by IL-
1β-stimulation of ASCs. The potential effect of ASCs on
PMNs was underlined in a murine sepsis model, where ASC-
induced phagocytosis by PMNs resulted in enhanced bacterial
clearance and lowered mortality (36). In a different study,
microarray analysis demonstrated that MSC treatment of
mice with the cecal ligation and puncture model of sepsis
resulted in enriched pathways for Fc receptor–mediated
phagocytosis, natural killer cell signaling, and antigen
presentation (37).
Phagocytosis is likely to be a crucial process in our CiOA
model as collagenase injections damage collateral ligaments
leading to mechanical instability of the joint (38). Insufficient
removal of tissue debris prolongs synovitis thereby contributing
to cartilage degradation and ectopic bone formation (21).
Enhanced removal of tissue debris by ASC-stimulated PMNs
may reduce the inflammatory response and simultaneously
clear the area for more effective repair of ligaments. This
would explain why we previously found less joint destruction
in end stage CiOA after ASC injection (17). PMN attraction
alone is not sufficient to reduce joint damage, since control
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injections without ASCs induced similar PMN influx but did
not protect the joint from developing cartilage and bone
destruction later on (17, 18). This supports our idea that
ASCs applied in an inflammatory environment not only
reallocate but also activate PMNs to protect the joint from
further destruction.
In search of soluble factors that stimulate ASCs to attract
PMNs, we focused on two pro-inflammatory mediators that
characterize synovitis in early CiOA. Firstly, the contribution
of the important TLR4 ligand S100A8/A9 to joint destruction
during CiOA is well-described (34, 39). Elevated levels of
S100A8/A9 have also been measured in OA patients (34,
40). A previous study showed that after stimulation with
the TLR4 ligand LPS MSCs produce inflammatory mediators
such as IL-1β, IL-6, and IL-8, indicating the expression of
TLR4 on the cell membrane of ASCs (41, 42). Unexpectedly,
S100A8/A9 did not induce the expression of KC or IL-8
by ASCs in vitro. This difference could be explained by the
observation that TLR4 signaling by S100A8/A9 is different
from that of LPS since S100A8/A9 signaling is independent of
CD14 (24).
Secondly, we focused on IL-1β that is elevated in synovium
and cartilage in OA patients (2, 43). Although the role of IL-
1β in human OA is still a matter of debate (44), we recently
showed that IL-1β does not contribute to CiOA pathology (45,
46). IL-1β directly induces the immunosuppressive phenotype
of ASCs via activation of NF-κB and JNK signaling pathways
(47) thereby stimulating several paracrine effects (48, 49). In
the current study we found that very low levels of IL-1β
strongly enhance gene and protein expression of PMN-attracting
chemokines KC in murine cells and IL-8 in human cells,
enabling a powerful amplification of PMN reallocation and
clustering with ASCs. This in turn enables the ASC-mediated
increase in phagocytosis in vitro, and possibly also in vivo. These
results emphasize that although IL-1β does not aggravate joint
destruction in CiOA, it may be a crucial factor for the ASC-
mediated protection against joint destruction that was published
before (16–18, 50). It also explains why ASC treatment is
only effective when applied early in inflammatory CiOA (17),
as elevated IL-1β levels are only present during early stages
(34). ASC treatment after induction of CiOA in IL-1β−/− mice
would be an elegant experiment to confirm the crucial role
of IL-1β.
The ultimate goal is to treat human OA patients with ASCs. In
line with previous mouse studies (17, 18, 27), a phase 1 human
trial showed that a single injection of a low number of ASCs into
knee joints of OA patients ameliorated pain and MRI analysis
of ASC-injected joints indicates reduced development of joint
destruction (16). Currently, a double blind phase IIb study called
ADIPOA2 is performed in which 150 OA patients will be treated
intra-articularly with autologous ASCs.
CONCLUSIONS
In our study we demonstrate that IL-1β-stimulated ASCs
reallocate inflammatory PMNs thereby inducing cluster
formation with ASCs, resulting in increased phagocytic capacity.
We found this not only with murine, but also with human cells.
These results may explain the previously published reduction
in OA pathology after ASC injection into an inflamed joint.
This more extensive knowledge of how intra-articular injection
of ASCs initiates the protective effect, and particularly which
factors drive this process, enables the prediction of the efficacy
of ASC treatment. This paves the way for the development of
well-defined inclusion criteria for OA patients.
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Supplementary Figure 1 | 20,000 ASCs protect more efficiently against synovial
inflammation in CiOA than 100,000 ASCs. On day 7 after induction of CiOA, two
groups of 22 mice were injected intra-articularly with either 20,000 ASCs or
100,000 ASCs in 6 µL saline supplemented with 1% bovine serum albumin (BSA)
fraction V. Twenty-two mice with CiOA were injected with only saline
supplemented with 1% BSA as control. On day 14 and 42, total knee joints with
CiOA were collected and stained with hematoxylin/eosin (HE) to score synovial
inflammation which was identified as thickening of the synovium (arbitrary score
from 0 to 3, three sections per knee joint). Intra-articular injection of 20,000 ASCs
resulted in significantly lower synovial inflammation in CiOA than injection of
100,000 ASCs on both day 14 and day 42. N = 11 per group. Differences
between groups were tested using a one-way ANOVA followed by a Bonferroni
Multiple Comparison posttest. Bars show mean values ± SD. ∗P < 0.05.
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